To Evaluate The Efficacy And Safety Of Rivaroxaban In Combination With Aspirin Compared With Aspirin Monotherapy In Patients With Stable Coronary Artery Disease (CAD) and High Ischemic Risk
Stable Coronary Artery Disease (CAD), Myocardial Infarction
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 18 years - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 200 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
This study compares rivaroxaban plus aspirin with aspirin alone in patients with stable coronary artery disease at high ischemic risk. The aim is to evaluate whether the combination therapy better prevents cardiovascular events and to assess its safety.
Read the full description
This study will compare the effectiveness and safety of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease who are at high risk of ischemic events. Participants will be randomly assigned to receive either rivaroxaban combined with aspirin or aspirin alone. The main goal is to determine whether the combination of rivaroxaban and aspirin reduces the risk of cardiovascular events (such as heart attack, stroke, or cardiovascular death) more effectively than aspirin monotherapy, while also assessing bleeding risks and overall safety.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Age 18 years or older
- Stable coronary artery disease
- High ischemic risk
- Able to provide informed consent
Exclusion Criteria:
- Active bleeding or high bleeding risk
- Contraindication to rivaroxaban or aspirin
- Severe renal or hepatic impairment
- Pregnancy or breastfeeding
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Random assignment
- Masking
- No masking
Arm Title: Rivaroxaban + Aspirin
Not reported in this registry record.
Drug: rivaroxaban plus aspirin
Arm Title: Aspirin
Aspirin monotherapy.
Drug: Aspirin 75 mg daily
rivaroxaban plus aspirin DRUG
Participants receive rivaroxaban in combination with aspirin.
Aspirin 75 mg daily DRUG
Aspirin monotherapy.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Composite of cardiovascular death, myocardial infarction, or stroke
Time frame: From randomization up to 36 months (or the duration of the study)
Time to first occurrence of cardiovascular death, myocardial infarction, or stroke.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (0)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
No locations are listed. Use the official study contact.
Study team and timeline
- Lead sponsor
- Republican Specialized Scientific and Practical Medical Center of Cardiology
- Study start
- Nov 5, 2026 Estimated
- Primary completion
- Nov 26, 2026 Estimated
- Study completion
- Dec 15, 2026 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
No central contact is listed. Check the locations and the official record.
Official study title
To Evaluate The Efficacy And Safety Of Rivaroxaban In Combination With Aspirin Compared With Aspirin Monotherapy In Patients With Stable Coronary Artery Disease (CAD) and High Ischemic Risk
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026